rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    VCYT
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Veracyte at Jefferies Global Healthcare Conference: decipher reset, growth plan
      13h agoInvesting.comVCYTJEF
      Veracyte: Solid Profits, Slowing Tests, And A Stock In Limbo

      Veracyte is a Hold: Decipher growth is slowing, with management planning a 40% lower annual increase; consensus expects 2027 EPS to fall 19.38%. Click for more on VCYT stock.

      Nov 12Seeking AlphaVCYT
      Veracyte at UBS Global Healthcare Conference: growth plan beyond Decipher
      Nov 10Investing.comVCYTUBS
      Veracyte (VCYT) Reset Decipher Growth Expectations, Is The Discount Now Too Wide?

      Why Veracyte Stock Is Back Under The Microscope Veracyte (VCYT) rattled investors after resetting near term expectations for its Decipher prostate cancer test, even as quarterly revenue growth remained solid and management trimmed 2026 guidance. The latest reset around Decipher came on top of a sharp swing in sentiment, with Veracyte’s share price down 51.69% over the past week and 48.84% over the last three months, while the 1-year total shareholder return has fallen 42.06% even though the...

      Nov 7Yahoo FinanceVCYT
      Why Is Veracyte (VCYT) Drawing Attention For Its Decipher Prostate Test?

      Veracyte (NasdaqGM:VCYT) reported new predictive data on its Decipher Prostate Genomic Classifier in very high-risk nonmetastatic prostate cancer. The findings support using Decipher to identify patients who may benefit from adding abiraterone to androgen deprivation therapy in this setting. The updated NCCN guidelines now recognize this evidence, giving the Decipher Prostate test formal guideline support in high-risk treatment decisions. The fresh predictive evidence and NCCN guideline...

      Nov 6Yahoo FinanceVCYT
      Veracyte Q3 Earnings Call Highlights Slower Growth and Added Investment
      Nov 6Yahoo FinanceVCYT
      Veracyte plunges 56% after updated 2026 revenue outlook (VCYT:NASDAQ)
      Nov 5Seeking AlphaVCYT
      Veracyte (VCYT) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Nov 5The Globe and MailVCYT
      Why Is Veracyte Stock Sinking Thursday?
      Nov 5BenzingaVCYT
      Veracyte stock downgraded at Leerink on guidance cut (VCYT)
      Nov 5Seeking AlphaVCYT
      Veracyte stock hits 52-week low at 28.81 USD
      Nov 5Investing.comVCYT
      Cancer-Testing Play Crashes Almost 40% On A Seismic Shift

      Veracyte stock crashed almost 40% early Thursday after the company reset growth expectations for its prostate cancer test.

      Nov 5Investor's Business DailyVCYT
      Why is Veracyte stock plummeting today?
      Nov 5Investing.comVCYT
      Needham cuts Veracyte stock price target to $46 on growth outlook
      Nov 5Investing.comVCYT
      Veracyte Inc (VCYT) Q3 2026 Earnings Call Highlights: Revenue Climbs 15% as Afirma Shines and ...
      Nov 5Yahoo FinanceVCYT
      What Veracyte (VCYT) Said on Its Q3 Earnings Call
      Nov 5Yahoo FinanceVCYT
      Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates
      Nov 4Yahoo FinanceVCYT
      Veracyte Q3 2026 Earnings Call Transcript
      Nov 4BenzingaVCYT
      Veracyte faces earnings test as profitability gains meet new products
      Nov 4Investing.comVCYT
      Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
      Oct 28Yahoo FinanceVCYT
      Clinical Trial Data Might Change The Case For Investing In Veracyte Stock (VCYT)
      Oct 28Yahoo FinanceVCYT
      Veracyte: Strong Diagnostic Growth And Improving Margins (NASDAQ:VCYT)

      Explore why Veracyte is rated a buy: strong test demand, 15% revenue growth, rising margins, and new product expansion. Click for more on VCYT stock.

      Oct 22Seeking AlphaVCYT
      Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?
      Oct 21Yahoo FinanceVCYT
      Veracyte director Muna Bhanji sells $81,456 in company stock
      Oct 21Investing.comVCYT
      Veracyte’s Prosigna breast cancer test receives Medicare coverage
      Oct 16Investing.comVCYT
      Veracyte (VCYT) Stock Still Looks Cheap As Its 107% Run Continues
      Oct 9Yahoo FinanceVCYT
      Cathie Wood’s ARK sells Teradyne stock, buys Veracyte
      Oct 7Investing.comTERVCYT
      Veracyte (VCYT) Could Be 22% Undervalued After New Decipher Phase III Data

      Veracyte (VCYT) is back in focus after new phase III data on its Decipher Prostate Genomic Classifier showed it can help identify which intermediate-risk prostate cancer patients benefit most from adding short-term hormone therapy. Investors have seen momentum cool in recent weeks, with Veracyte’s share price falling 4.0% on the day and 9.0% over the past week, while the 90 day share price return is down 22.6%. Yet the 1 year total shareholder return of 24.0% and 3 year total shareholder...

      Oct 2Yahoo FinanceVCYT
      Veracyte (VCYT) Is Down 9.0% After New Level 1B1 Decipher Prostate Data at ASTRO 2026
      Oct 2Yahoo FinanceVCYT
      Could Veracyte (VCYT) Change Prostate Cancer Care With New Phase III Data?

      Veracyte (NasdaqGM:VCYT) reported new phase III data showing its Decipher Prostate Genomic Classifier can guide hormone therapy use with radiation in intermediate-risk prostate cancer. The phase III trial provided prospective evidence that Decipher can help identify which patients are more likely to benefit from adding hormone therapy to radiation treatment. Findings suggest Decipher may extend its role from prognosis to predicting treatment benefit, potentially influencing how clinicians...

      Oct 1Yahoo FinanceVCYT
      Veracyte’s Decipher test shows predictive value in prostate cancer
      Sep 29Investing.comVCYT
      Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains?

      Veracyte (VCYT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

      Sep 25Yahoo FinanceVCYT
      Veracyte global chief commercial off. John Leite sells $160,600 stock
      Sep 23Investing.comVCYT
      Veracyte at Morgan Stanley conference: growth, deals and new tests
      Sep 15Investing.comVCYTMS
      Needham reiterates Veracyte stock rating at Buy on genomics deal
      Sep 15Investing.comVCYT
      Veracyte Adds Another Stream to Bladder Franchise, UBS Says

      Veracyte (VCYT) is adding an adjacent product to its bladder franchise following its acquisition of

      Sep 15Yahoo FinanceVCYT
      Veracyte acquires Convergent Genomics for up to $180 million
      Sep 14Investing.comVCYT
      Veracyte Buys Convergent Genomics

      Veracyte (VCYT) said late Monday it has acquired Convergent Genomics for $150 million in upfront cas

      Sep 14Yahoo FinanceVCYT
      Veracyte (VCYT) Gets a Buy from UBS

      Detailed price information for Veracyte Inc (VCYT-Q) from The Globe and Mail including charting and trades.

      Sep 10The Globe and MailVCYT
      Zacks Industry Outlook Highlights Veracyte, Globus Medical and UFP Technologies

      Veracyte, Globus Medical and UFP Technologies are positioned to benefit as GenAI adoption reshapes medical instruments.

      Sep 10Yahoo FinanceVCYTGMED
      UBS Adjusts Price Target on Veracyte to $65 From $52, Keeps Buy Rating
      Sep 9Yahoo FinanceVCYT
      Veracyte CFO Rebecca Chambers sells $157,394 in VCYT shares
      Sep 5Investing.comVCYT
      Veracyte chief scientific & med officer sells over $564k stock
      Sep 5Investing.comVCYT
      Veracyte EVP, general counsel Annie McGuire sells over $140,000 in stock
      Sep 5Investing.comVCYT
      Cathie Wood’s ARK sells Tempus AI stock, buys Veracyte
      Aug 28Investing.comTEMVCYT
      Is it Worth Adding Veracyte Stock to Your Portfolio Now?

      VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.

      Aug 26Yahoo FinanceVCYT
      Veracyte (VCYT) Receives a Buy from Piper Sandler

      Detailed price information for Veracyte Inc (VCYT-Q) from The Globe and Mail including charting and trades.

      Aug 25The Globe and MailVCYT
      VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?

      Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.

      Aug 25Yahoo FinanceVCYT

      This is the newest page. Registered accounts read further back.